Literature DB >> 8471371

Pharmacokinetics of flumazenil and midazolam.

R D Jones1, K Chan, C J Roulson, A G Brown, I D Smith, G H Mya.   

Abstract

We have studied simultaneously the pharmacokinetics of flumazenil and midazolam in 12 healthy Chinese children, aged 5-9 yr, undergoing circumcision. Two hours before operation each patient received midazolam 0.5 mg kg-1 orally for premedication and 0.5 mg kg-1 i.v. during induction. Six minutes after cessation of anaesthesia, a bolus of flumazenil 10 micrograms kg-1 was given i.v., followed by an infusion of flumazenil at 5 micrograms kg-1 min-1 which was maintained until the child could identify himself. Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15.4 (3.2) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.9 (0.6) litre kg-1. Flumazenil data were best interpreted by a monoexponential function, with a mean terminal elimination half-life of 35.3 (13.8) min, a total plasma clearance of 20.6 (6.9) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.0 (0.2) litre kg-1. No unchanged midazolam was detected in the 24-h urine sample, but 5.8-13.8% of the flumazenil dose was recovered unchanged. At the time of self identification, 4.5 (1.4) min after flumazenil administration, the mean plasma concentrations of midazolam and flumazenil were 163.1 (43.7) and 29.9 (16.1) ng ml-1, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471371     DOI: 10.1093/bja/70.3.286

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  14 in total

1.  Pharmacokinetics of midazolam in critically ill pediatric patients.

Authors:  M C Nahara; J McMorrow; P R Jones; D Anglin; R Rosenberg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Emergency analgesia in the paediatric population. Part IV Paediatric sedation in the accident and emergency department: pros and cons.

Authors:  E Doyle
Journal:  Emerg Med J       Date:  2002-07       Impact factor: 2.740

3.  Average recovery time from a standardized intravenous sedation protocol and standardized discharge criteria in the general dental practice setting.

Authors:  A J Lepere; L M Slack-Smith
Journal:  Anesth Prog       Date:  2002

Review 4.  A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.

Authors:  A A Weinbroum; R Flaishon; P Sorkine; O Szold; V Rudick
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

5.  Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.

Authors:  Philip W Moore; J Ward Donovan; Keith K Burkhart; Jeffrey A Waskin; Michelle A Hieger; Audrey R Adkins; Yijin Wert; David A Haggerty; J J Rasimas
Journal:  J Med Toxicol       Date:  2014-06

Review 6.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

7.  A comparison of intramuscular ketamine with high dose intramuscular midazolam with and without intranasal flumazenil in children before suturing.

Authors:  R McGlone; T Fleet; S Durham; S Hollis
Journal:  Emerg Med J       Date:  2001-01       Impact factor: 2.740

8.  Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon.

Authors:  M J Ford; M Camilleri; J A Wiste; R B Hanson
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

9.  Effect of cholecystokinin octapeptide and atropine on human colonic motility, tone, and transit.

Authors:  M D O'Brien; M Camilleri; G M Thomforde; J A Wiste; R B Hanson; A R Zinsmeister
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

Review 10.  Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.

Authors:  Ibrahim Ince; Catherijne A J Knibbe; Meindert Danhof; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.